Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Braz J Microbiol ; 50(1): 67-77, 2019 Jan.
Article in English | MEDLINE | ID: mdl-30637647

ABSTRACT

Microlipid vesicles (MLV) have a broad spectrum of applications for the delivery of molecules, ranging from chemical compounds to proteins, in both in vitro and in vivo conditions. In the present study, we developed a new set of nanosize multilayer lipid vesicles (NMVs) containing a unique combination of lipids. The NMVs enable the adsorption of histidine-tagged proteins at the vesicle surface and were demonstrated to be suitable for the in vivo delivery of antigens. The NMVs contained a combination of neutral (DOPC) and anionic (DPPG) lipids in the inner membrane and an external layer composed of DOPC, cholesterol, and a nickel-containing lipid (DGS-NTA [Ni]). NMVs combined with a recombinant form of the B subunit of the Shiga toxin (rStx2B) produced by certain enterohemorragic Escherichia coli (EHEC) strains enhanced the immunogenicity of the antigen after parenteral administration to mice. Mice immunized with rStx2B-loaded NMVs elicited serum antibodies capable of neutralizing the toxic activities of the native toxin; this result was demonstrated both in vitro and in vivo. Taken together, these results demonstrated that the proposed NMVs represent an alternative for the delivery of antigens, including recombinant proteins, generated in different expression systems.


Subject(s)
Antibodies, Bacterial/immunology , Drug Delivery Systems/methods , Enterohemorrhagic Escherichia coli/immunology , Escherichia coli Infections/immunology , Lipids/chemistry , Shiga Toxin/immunology , Animals , Antibody Formation , Antigens, Bacterial/administration & dosage , Antigens, Bacterial/chemistry , Antigens, Bacterial/immunology , Drug Carriers/administration & dosage , Drug Carriers/chemistry , Drug Delivery Systems/instrumentation , Enterohemorrhagic Escherichia coli/genetics , Escherichia coli Infections/microbiology , Escherichia coli Infections/prevention & control , Female , Humans , Immunization , Mice , Mice, Inbred BALB C , Nanoparticles/administration & dosage , Nanoparticles/chemistry , Shiga Toxin/administration & dosage , Shiga Toxin/chemistry
2.
Article in English | MEDLINE | ID: mdl-27747196

ABSTRACT

Seizures and neurologic involvement have been reported in patients infected with Shiga toxin (Stx) producing E. coli, and hemolytic uremic syndrome (HUS) with neurologic involvement is associated with more severe outcome. We investigated the extent of renal and neurologic damage in mice following injection of the highly potent form of Stx, Stx2a, and less potent Stx1. As observed in previous studies, Stx2a brought about moderate to acute tubular necrosis of proximal and distal tubules in the kidneys. Brain sections stained with hematoxylin and eosin (H&E) appeared normal, although some red blood cell congestion was observed. Microglial cell responses to neural injury include up-regulation of surface-marker expression (e.g., Iba1) and stereotypical morphological changes. Mice injected with Stx2a showed increased Iba1 staining, mild morphological changes associated with microglial activation (thickening of processes), and increased microglial staining per unit area. Microglial changes were observed in the cortex, hippocampus, and amygdala regions, but not the nucleus. Magnetic resonance imaging (MRI) of Stx2a-treated mice revealed no hyper-intensities in the brain, although magnetic resonance spectroscopy (MRS) revealed significantly decreased levels of phosphocreatine in the thalamus. Less dramatic changes were observed following Stx1 challenge. Neither immortalized microvascular endothelial cells from the cerebral cortex of mice (bEnd.3) nor primary human brain microvascular endothelial cells were found to be susceptible to Stx1 or Stx2a. The lack of susceptibility to Stx for both cell types correlated with an absence of receptor expression. These studies indicate Stx causes subtle, but identifiable changes in the mouse brain.


Subject(s)
Disease Models, Animal , Nervous System/drug effects , Nervous System/pathology , Shiga Toxin/toxicity , Amygdala/drug effects , Amygdala/pathology , Animals , Brain/drug effects , Brain/metabolism , Brain/pathology , Calcium-Binding Proteins , Cell Culture Techniques , Cerebral Cortex/drug effects , Cerebral Cortex/pathology , DNA-Binding Proteins , Endothelial Cells/drug effects , Endothelial Cells/pathology , Erythrocytes/drug effects , Escherichia coli/metabolism , Escherichia coli/pathogenicity , Hemolytic-Uremic Syndrome/microbiology , Hemolytic-Uremic Syndrome/pathology , Hippocampus/drug effects , Hippocampus/pathology , Humans , Kidney/drug effects , Kidney/pathology , Magnetic Resonance Imaging/methods , Male , Mice , Microfilament Proteins , Microglia/drug effects , Microglia/pathology , Phosphocreatine/analysis , Rabbits , Repressor Proteins , Shiga Toxin/administration & dosage , Shiga Toxin 2/administration & dosage , Shiga Toxin 2/toxicity , Spectrum Analysis/methods , Thalamus/chemistry , Toxicity Tests/methods , Tumor Necrosis Factor-alpha/pharmacology , Weight Gain/drug effects , Weight Loss/drug effects
3.
Nephrol Dial Transplant ; 30(6): 969-77, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25694534

ABSTRACT

BACKGROUND: Recombinant human soluble thrombomodulin (rhTM) is a promising therapeutic natural anticoagulant that is comparable to antithrombin, tissue factor pathway inhibitor and activated protein C. In order to clarify the efficacy of rhTM for the treatment of typical hemolytic uremic syndrome (t-HUS), we examined changes in renal damage in t-HUS mice treated with rhTM or vehicle alone. METHODS: We used severe and moderate t-HUS mice injected with shiga toxin (Stx) and lipopolysaccharide (LPS). The severe t-HUS mice were divided into two subgroups [an rhTM subgroup (Group A) and a saline subgroup (Group B)] along with the moderate t-HUS mice [an rhTM subgroup (Group C) and a saline subgroup (Group D)]. Groups E and F were healthy mice treated with rhTM or saline, respectively. RESULTS: All mice in Group B died at 80-90 h post-administration of Stx2 and LPS whereas all mice in Group A remained alive. Loss of body weight, serum creatinine level, endothelial injury and mesangiolysis scores at 24 h after administration in the t-HUS mice treated with rhTM were lower than those in t-HUS mice treated with saline. The levels of hemoglobin at 6 h and platelet counts at 24 h after administration in Group A were higher than those in Group B. Serum interleukin (IL)-6, IL-1ß and tumor necrotic factor (TNF)-α levels at 24 h after administration in Group A were lower than those in Group B. Serum C5b-9 levels at 24 h after the administration and serum fibrinogen degradation product (FDP) at 72 h after the administration of Stx2 and LPS were lower in Group A than in Group B. CONCLUSIONS: These results indicate that rhTM might afford an efficacious treatment for t-HUS model mice via the inhibition of further thrombin formation and amelioration of hypercoagulant status.


Subject(s)
Disease Models, Animal , Hemolytic-Uremic Syndrome/therapy , Lipopolysaccharides/administration & dosage , Recombinant Proteins/therapeutic use , Shiga Toxin/administration & dosage , Thrombomodulin/metabolism , Animals , Complement Membrane Attack Complex , Hemolytic-Uremic Syndrome/metabolism , Hemolytic-Uremic Syndrome/pathology , Humans , Immunoenzyme Techniques , Interleukin-1beta/metabolism , Interleukin-6/metabolism , Kidney/pathology , Male , Mice , Mice, Inbred C57BL , Thrombomodulin/genetics , Treatment Outcome , Tumor Necrosis Factor-alpha/metabolism
4.
J Immunol ; 189(7): 3661-8, 2012 Oct 01.
Article in English | MEDLINE | ID: mdl-22942429

ABSTRACT

Shiga toxin (Stx)-producing Escherichia coli is a primary cause of diarrhea-associated hemolytic uremic syndrome (HUS), a disorder of thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure. The pathophysiology of renal microvascular thrombosis in Stx-HUS is still ill-defined. Based on evidence that abnormalities in thrombomodulin (TM), an anticoagulant endothelial glycoprotein that modulates complement and inflammation, predispose to atypical HUS, we assessed whether impaired TM function may adversely affect evolution of Stx-HUS. Disease was induced by coinjection of Stx2/LPS in wild-type mice (TM(wt/wt)) and mice that lack the lectin-like domain of TM (TM(LeD/LeD)), which is critical for its anti-inflammatory and cytoprotective properties. After Stx2/LPS, TM(LeD/LeD) mice exhibited more severe thrombocytopenia and renal dysfunction than TM(wt/wt) mice. Lack of lectin-like domain of TM resulted in a stronger inflammatory reaction after Stx2/LPS with more neutrophils and monocytes/macrophages infiltrating the kidney, associated with PECAM-1 and chemokine upregulation. After Stx2/LPS, intraglomerular fibrin(ogen) deposits were detected earlier in TM(LeD/LeD) than in TM(wt/wt) mice. More abundant fibrin(ogen) deposits were also found in brain and lungs. Under basal conditions, TM(LeD/LeD) mice exhibited excess glomerular C3 deposits, indicating impaired complement regulation in the kidney that could lead to local accumulation of proinflammatory products. TM(LeD/LeD) mice with HUS had a higher mortality rate than TM(wt/wt) mice. If applicable to humans, these findings raise the possibility that genetic or acquired TM defects might have an impact on the severity of microangiopathic lesions after exposure to Stx-producing E. coli infections and raise the potential for using soluble TM in the treatment of Stx-HUS.


Subject(s)
Hemolytic-Uremic Syndrome/genetics , Hemolytic-Uremic Syndrome/immunology , Lectins/deficiency , Shiga Toxin/administration & dosage , Thrombomodulin/deficiency , Thrombomodulin/genetics , Animals , Hemolytic-Uremic Syndrome/chemically induced , Male , Mice , Mice, 129 Strain , Mice, Transgenic , Protein Structure, Tertiary/genetics , Severity of Illness Index , Thrombomodulin/physiology
5.
Vaccine ; 29(45): 8094-100, 2011 Oct 19.
Article in English | MEDLINE | ID: mdl-21856355

ABSTRACT

Shigella dysenteriae is the causative agent of the third commonest bacterial disease for childhood diarrhoea and responsible for millions of deaths per year. It produces potent toxin termed Shiga toxin which is listed in category B biological warfare agent of CDC, USA. Earlier we have reported production of recombinant Shiga toxin B subunit that produced antibodies which neutralized Shiga toxin toxicity in HeLa cells. In the present study, we have evaluated the immunomodulatory potential of rStxB protein in Balb/c mice using Freunds adjuvants. Animal protection with recombinant StxB was conferred through both humoral and cellular immune responses as indicated by an increased antibody titre with predominance of IgG2a and IgG2b isotypes along with elevated levels of IgG1 subtype. Cytokine profile of the mice antiserum and splenocyte also indicates Th2 and Th1 type of immune responses where former dominates in early stage of immunization. Histopathology study of kidneys of vaccinated mice showed remarkable differences when compared to the animals infected with Shigella dysenteriae type1. The present study indicates that recombinant StxB is a promising vaccine candidate and can be used for production of therapeutic antibodies to counter Shiga intoxication.


Subject(s)
Shiga Toxin/immunology , Shigella Vaccines/immunology , Adjuvants, Immunologic/administration & dosage , Animals , Antibodies, Bacterial/blood , Antitoxins/blood , Cytokines/blood , Cytokines/metabolism , Dysentery, Bacillary/pathology , Dysentery, Bacillary/prevention & control , Female , Freund's Adjuvant/administration & dosage , Histocytochemistry , Immunoglobulin G/blood , Kidney/pathology , Leukocytes, Mononuclear/immunology , Mice , Mice, Inbred BALB C , Protein Subunits/administration & dosage , Protein Subunits/immunology , Shiga Toxin/administration & dosage , Shigella Vaccines/administration & dosage , Shigella dysenteriae/immunology , Shigella dysenteriae/pathogenicity , Spleen/immunology , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/immunology
6.
Nephrol Dial Transplant ; 23(10): 3091-5, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18469308

ABSTRACT

BACKGROUND: Shiga toxin (Stx) is the main pathogenic factor in the haemolytic-uraemic syndrome (HUS). Stx damages the renal endothelium, which leads to inflammation and coagulation. Endothelial heparan sulfate proteoglycans (HSPG), and heparan sulfate in particular, play an important role in the inflammatory process by acting as a ligand for l-selectin. Furthermore, leukocytes are able to interact with chemokines bound to HSPG (examples are IL-8, RANTES and MCP-1). This leads to an activation of integrins on leukocytes and results in more stable leukocyte-endothelial wall adhesion. In this study, we have evaluated the effect of a subtoxic dose of Stx1 and Stx2 on the HSPG and its role in adhesion of leukocytes. METHODS: Primary human umbilical venous endothelial cells (HUVEC) and primary human glomerular microvascular endothelial cells (GMVEC) were incubated for 24 h with a subtoxic dose of Stx1 or Stx2. Then, cells were treated with heparan sulfate-degrading enzyme heparitinase I or left untreated, followed by determination of binding leukocytes to endothelial cells in a parallel plate flow chamber. RESULTS: In both cell types, Stx increased the amount of firmly adherent leukocytes. After removal of endothelial heparan sulfate, the number of adhering leukocytes decreased. CONCLUSIONS: HSPG have a distinctive role in adhesion of leukocytes to endothelial cells stimulated by a subtoxic dose of Stx.


Subject(s)
Cell Adhesion/drug effects , Cell Adhesion/physiology , Endothelial Cells/drug effects , Endothelial Cells/physiology , Heparitin Sulfate/physiology , Leukocytes/drug effects , Leukocytes/physiology , Shiga Toxin/toxicity , Cells, Cultured , Hemolytic-Uremic Syndrome/etiology , Heparan Sulfate Proteoglycans/physiology , Humans , Polysaccharide-Lyases/pharmacology , Shiga Toxin/administration & dosage , Shiga Toxin 1/administration & dosage , Shiga Toxin 1/toxicity , Shiga Toxin 2/administration & dosage , Shiga Toxin 2/toxicity
7.
Clin Vaccine Immunol ; 15(2): 359-66, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18003816

ABSTRACT

Enterohemorrhagic Escherichia coli (EHEC) strains are important human food-borne pathogens. EHEC strains elaborate potent Shiga toxins (Stx1, and/or Stx2) implicated in the development of hemorrhagic colitis (HC) or hemolytic-uremic syndrome (HUS). In this report, we evaluated the immunogenicity and protective efficacy of Stx1 subunit B (StxB1) administered by transcutaneous immunization (TCI). Three groups of Dutch Belted rabbits received patches containing StxB1, StxB1 in combination with Escherichia coli heat-labile enterotoxin (LT), or LT alone. An additional group of naïve rabbits served as controls. The protective efficacy following TCI with StxB1 was assessed by challenging rabbits with a virulent Stx1-producing strain, RDEC-H19A, capable of inducing HC and HUS in rabbits. Antibodies specific to StxB1 from serum and bile samples were determined by enzyme-linked immunosorbent assay and toxin neutralization test. Rabbits immunized with StxB1 demonstrated improved weight gain and reduced Stx-induced histopathology. Rabbits receiving StxB or StxB1/LT showed a significant increase in serum immunoglobulin G titers specific to StxB1 as well as toxin neutralization titers. These data demonstrated that the StxB delivered by TCI could induce significant systemic immune responses. Thus, Stx subunit B vaccine delivered by a patch for a high-risk population may be a practical approach to prevent (and/or reduce) Stx-induced pathology.


Subject(s)
Administration, Cutaneous , Escherichia coli Infections/prevention & control , Shiga Toxin/immunology , Shiga-Toxigenic Escherichia coli/immunology , Adjuvants, Immunologic/administration & dosage , Animals , Antibodies, Bacterial/analysis , Antibodies, Bacterial/blood , Antitoxins/analysis , Antitoxins/blood , Bacterial Toxins/administration & dosage , Bile/immunology , Body Weight/immunology , Cecum/pathology , Colitis/prevention & control , Enterotoxins/administration & dosage , Escherichia coli Infections/immunology , Escherichia coli Proteins/administration & dosage , Feces/microbiology , Hemolytic-Uremic Syndrome/prevention & control , Intestinal Mucosa/pathology , Kidney/pathology , Protein Subunits/administration & dosage , Protein Subunits/immunology , Rabbits , Serum/immunology , Shiga Toxin/administration & dosage , Vaccines, Subunit/administration & dosage , Vaccines, Subunit/immunology
8.
Nano Lett ; 7(9): 2718-23, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17655369

ABSTRACT

Silica nanowires (NWs) were used to introduce the Shiga toxin type 1 A subunit (StxA1) into cultured bovine and human epithelial cells. We extended technology developed in our laboratories that employs fibronectin (Fn) to induce integrin-mediated uptake of NWs by coating NWs with StxA1 and Fn. The bonding strengths of Fn and StxA1 to the surface of NWs were measured by X-ray photoelectron spectroscopy. This technique demonstrated complex interactions between Fn, StxA1, and the NWs. Neutral red cytotoxicity assays and field emission scanning electron microscopy confirmed that the NW-StxA1-Fn complexes were effectively internalized and caused cell death. This indicates that NWs can carry StxA1 and potentially other toxic or therapeutic agents into eukaryotic cells. Ongoing studies include improved functionalizing of NWs aimed at increasing internalization efficiency and substituting ligands for specific cell targeting.


Subject(s)
Cell Survival/drug effects , Drug Carriers/administration & dosage , Escherichia coli O157/metabolism , Nanostructures/chemistry , Nanotubes/chemistry , Protein Subunits/administration & dosage , Protein Subunits/chemistry , Shiga Toxin/administration & dosage , Shiga Toxin/chemistry , Animals , Cattle , Crystallization/methods , Drug Carriers/chemistry , Drug Carriers/pharmacokinetics , Drug Compounding/methods , Humans , Materials Testing , Nanostructures/ultrastructure , Nanotechnology/methods , Nanotubes/ultrastructure , Particle Size , Protein Subunits/pharmacokinetics , Shiga Toxin/pharmacokinetics
9.
Drugs Today (Barc) ; 39(9): 673-93, 2003 Sep.
Article in English | MEDLINE | ID: mdl-14586483

ABSTRACT

Infection with Shiga toxin-producing (Stx) Escherichia coli (STEC) currently represents a serious public health problem due to its life-threatening complications: hemorrhagic colitis and hemolytic uremic syndrome. An inability to induce neutralizing antibody in response to primary STEC infection has been reported in STEC-infected humans. Therefore, active immunization with detoxified Stx to induce the production of neutralizing antibodies against Stx is currently an attractive option. Although this would not prevent the spread of infection, it would protect against death caused by cytotoxin-producing E. coli infection. Stx coupled with liposomes effectively induced protection against challenge with lethal doses of Stx in mice and in monkeys. Unique characteristics of antigen-liposome conjugates found in our investigations are reviewed, and the possible application of Stx-liposome conjugates in vaccines for the prevention of life-threatening systemic complications caused by STEC infection is discussed.


Subject(s)
Escherichia coli Vaccines/immunology , Liposomes/immunology , Shiga Toxin/immunology , Escherichia coli Infections/prevention & control , Escherichia coli Infections/therapy , Escherichia coli Vaccines/administration & dosage , Humans , Immunotherapy , Liposomes/administration & dosage , Shiga Toxin/administration & dosage
11.
J Control Release ; 74(1-3): 349-55, 2001 Jul 06.
Article in English | MEDLINE | ID: mdl-11489517

ABSTRACT

Growing endothelial cells at sites of angiogenesis may be more sensitive than quiescent endothelial cells to toxin-VEGF fusion proteins, because they express higher numbers of VEGF receptors. We have constructed, expressed and purified a protein containing the catalytic A-subunit of Shiga-like toxin I fused to VEGF(121) (SLT-VEGF/L). SLT-VEGF/L inhibits protein synthesis in a cell-free translation system and induces VEGFR-2 tyrosine autophosphorylation in cells overexpressing VEGFR-2 indicating that both SLT and VEGF moieties are properly folded in the fusion protein. SLT-VEGF/L selectively inhibits growth of porcine endothelial cells expressing 2-3x10(5) VEGFR-2/cell with an IC(50) of 0.1 nM, and rapidly induces apoptosis at concentrations >1 nM. Similar results are observed with human transformed embryonic kidney cells, 293, engineered to express 2.5x10(6) VEGFR-2/cell. In contrast, SLT-VEGF/L does not affect three different types of endothelial cells (PAE/KDR(low), HUVE, MS1) expressing between 5x10(3) and 5x10(4) VEGFR-2/cell, and quiescent endothelial cells overexpressing VEGFR-2. Growth inhibition and induction of apoptosis by SLT-VEGF/L require intrinsic N-glycosidase activity of the SLT moiety, but occur without significant inhibition of protein synthesis. The selective cytotoxicity of SLT-VEGF proteins against growing endothelial cells overexpressing VEGFR-2 suggests that they may be useful in targeting similar cells at sites of angiogenesis.


Subject(s)
Endothelial Growth Factors/pharmacology , Endothelium, Vascular/cytology , Lymphokines/pharmacology , Receptor Protein-Tyrosine Kinases/biosynthesis , Receptors, Growth Factor/biosynthesis , Shiga Toxin/pharmacology , Animals , Blotting, Western , Caspase 6 , Caspases/biosynthesis , Cell Survival/drug effects , DNA/administration & dosage , DNA/genetics , Endothelial Growth Factors/administration & dosage , Endothelium, Vascular/drug effects , Humans , Lymphokines/administration & dosage , Receptors, Vascular Endothelial Growth Factor , Recombinant Fusion Proteins/administration & dosage , Recombinant Fusion Proteins/pharmacology , Shiga Toxin/administration & dosage , Swine , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...